👉 Most biotech founders think fundraising stalls because investors do not fully understand the science. In reality, biotech fundraising rarely fails on science alone . It fails when investors sense hesitation behind decisions, blurred priorities between milestones, or leadership teams that cannot clearly articulate what matters most right now. 👉 These signals appear in the first conversations, long before a term sheet is discussed. Fundraising is not a performance. It is a

👉 The start of a new year creates a natural moment for reflection and recalibration. Budgets are reviewed. Scientific priorities are discussed. Fundraising timelines are adjusted. Yet one decision often remains unchanged from the previous year. 👉 Patent strategy is treated as something already decided rather than something that deserves fresh leadership attention . For smart biotech CEOs, this is a missed opportunity. A company does not enter January in the same position it

The paradox of “great data, no funding.” You have the data. The models are working. Your preclinical package is strong. ✅ Clean PK PD ✅ A validated mechanism of action ✅ Consistent dose curves ✅ Promising in vivo results Biotech founders reach this point and expect momentum. But instead, investor meetings stall. Because no matter how strong the science looks, biotech investors keep asking the same uncomfortable questions: 👉 “What’s the actual market here?” 👉 “How urgent i